IBDEI0KI ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9047,1,4,0)
 ;;=4^N04.5
 ;;^UTILITY(U,$J,358.3,9047,2)
 ;;=^5015536
 ;;^UTILITY(U,$J,358.3,9048,0)
 ;;=N04.6^^69^617^52
 ;;^UTILITY(U,$J,358.3,9048,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9048,1,3,0)
 ;;=3^Nephrotic syndrome w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,9048,1,4,0)
 ;;=4^N04.6
 ;;^UTILITY(U,$J,358.3,9048,2)
 ;;=^5015537
 ;;^UTILITY(U,$J,358.3,9049,0)
 ;;=N04.7^^69^617^53
 ;;^UTILITY(U,$J,358.3,9049,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9049,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse crescentic glomerulonephritis
 ;;^UTILITY(U,$J,358.3,9049,1,4,0)
 ;;=4^N04.7
 ;;^UTILITY(U,$J,358.3,9049,2)
 ;;=^5015538
 ;;^UTILITY(U,$J,358.3,9050,0)
 ;;=N04.8^^69^617^60
 ;;^UTILITY(U,$J,358.3,9050,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9050,1,3,0)
 ;;=3^Nephrotic syndrome w/ other morphologic changes
 ;;^UTILITY(U,$J,358.3,9050,1,4,0)
 ;;=4^N04.8
 ;;^UTILITY(U,$J,358.3,9050,2)
 ;;=^5015539
 ;;^UTILITY(U,$J,358.3,9051,0)
 ;;=N04.9^^69^617^61
 ;;^UTILITY(U,$J,358.3,9051,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9051,1,3,0)
 ;;=3^Nephrotic syndrome w/ unspecified morphologic changes
 ;;^UTILITY(U,$J,358.3,9051,1,4,0)
 ;;=4^N04.9
 ;;^UTILITY(U,$J,358.3,9051,2)
 ;;=^5015540
 ;;^UTILITY(U,$J,358.3,9052,0)
 ;;=N05.0^^69^617^49
 ;;^UTILITY(U,$J,358.3,9052,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9052,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,9052,1,4,0)
 ;;=4^N05.0
 ;;^UTILITY(U,$J,358.3,9052,2)
 ;;=^5015541
 ;;^UTILITY(U,$J,358.3,9053,0)
 ;;=N05.1^^69^617^48
 ;;^UTILITY(U,$J,358.3,9053,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9053,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ focal & segmental glomerular lesions
 ;;^UTILITY(U,$J,358.3,9053,1,4,0)
 ;;=4^N05.1
 ;;^UTILITY(U,$J,358.3,9053,2)
 ;;=^5015542
 ;;^UTILITY(U,$J,358.3,9054,0)
 ;;=N05.2^^69^617^45
 ;;^UTILITY(U,$J,358.3,9054,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9054,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,9054,1,4,0)
 ;;=4^N05.2
 ;;^UTILITY(U,$J,358.3,9054,2)
 ;;=^5015543
 ;;^UTILITY(U,$J,358.3,9055,0)
 ;;=N05.3^^69^617^46
 ;;^UTILITY(U,$J,358.3,9055,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9055,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,9055,1,4,0)
 ;;=4^N05.3
 ;;^UTILITY(U,$J,358.3,9055,2)
 ;;=^5015544
 ;;^UTILITY(U,$J,358.3,9056,0)
 ;;=N05.4^^69^617^44
 ;;^UTILITY(U,$J,358.3,9056,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9056,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ diffuse endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,9056,1,4,0)
 ;;=4^N05.4
 ;;^UTILITY(U,$J,358.3,9056,2)
 ;;=^5015545
 ;;^UTILITY(U,$J,358.3,9057,0)
 ;;=N05.5^^69^617^47
 ;;^UTILITY(U,$J,358.3,9057,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9057,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,9057,1,4,0)
 ;;=4^N05.5
 ;;^UTILITY(U,$J,358.3,9057,2)
 ;;=^5015546
 ;;^UTILITY(U,$J,358.3,9058,0)
 ;;=N05.6^^69^617^42
 ;;^UTILITY(U,$J,358.3,9058,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9058,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,9058,1,4,0)
 ;;=4^N05.6
 ;;^UTILITY(U,$J,358.3,9058,2)
 ;;=^5015547
 ;;^UTILITY(U,$J,358.3,9059,0)
 ;;=N05.7^^69^617^43
 ;;^UTILITY(U,$J,358.3,9059,1,0)
 ;;=^358.31IA^4^2
